Document is current
Any future updates will be listed below
-
Authors
Gong, Wenjian https://orcid.org/0009-0001-3247-1224
Liao, Zhiqi
Xiong, Fan
Wang, Linghui
Shi, Shennan
Luo, Mengshi
Zhang, Yuewen
Xu, Qiuyang
Wang, Yuanyuan
Wu, Yijie
Zhu, Li
Kuang, Dong
Labrie, Marilyne https://orcid.org/0000-0003-3957-5533
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Ma, Ding https://orcid.org/0000-0003-3317-7016
Liu, Dan https://orcid.org/0000-0002-9971-2264
Zhao, Guang-Nian https://orcid.org/0000-0002-3112-7595
Gao, Qinglei https://orcid.org/0000-0002-9448-3423
Fang, Yong https://orcid.org/0000-0003-3412-8208
-
Funding
Funding for this research was provided by:
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (82272707)
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (82441045)
National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (81874109)
- License Information
-
More Information
Article History
Received: 22 August 2024
Accepted: 10 November 2025
First Online: 27 November 2025
Competing interests
: G.B.M.—SAB/Consultant: AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nano-string, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, Turbine; Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nano-string. The remaining authors declare no competing interests.
